ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024
ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company specializing in immunology, has announced its upcoming second quarter 2024 financial results and corporate update. The company will host a conference call on Tuesday, August 13, 2024, at 5:00 p.m. ET to discuss these matters. Investors and interested parties can access a live webcast of the conference call through the company's website under the Events & Presentations section. For those unable to attend the live event, a replay of the webcast will be available on ACELYRIN's website for 90 days following the call, providing ample opportunity for stakeholders to review the information presented.
ACELYRIN, INC. (Nasdaq: SLRN), una società biopharma clinica in fase avanzata specializzata in immunologia, ha annunciato i prossimi risultati finanziari del secondo trimestre 2024 e un aggiornamento aziendale. L'azienda organizzerà una call di conferenza martedì 13 agosto 2024, alle 17:00 ET per discutere di questi temi. Gli investitori e le parti interessate possono accedere a un webinar dal vivo della call attraverso il sito web dell'azienda nella sezione Eventi e Presentazioni. Per coloro che non possono partecipare all'evento dal vivo, un filmato della trasmissione sarà disponibile sul sito di ACELYRIN per 90 giorni dopo la call, offrendo ampie opportunità agli stakeholder di rivedere le informazioni presentate.
ACELYRIN, INC. (Nasdaq: SLRN), una empresa biopharma clínica en etapa avanzada especializada en inmunología, ha anunciado sus resultados financieros del segundo trimestre de 2024 y una actualización corporativa. La compañía llevará a cabo una llamada de conferencia el martes 13 de agosto de 2024 a las 5:00 p.m. ET para discutir estos temas. Los inversores y las partes interesadas pueden acceder a un webcast en vivo de la llamada a través del sitio web de la empresa en la sección de Eventos y Presentaciones. Para aquellos que no puedan asistir al evento en vivo, una repetición de la transmisión estará disponible en el sitio web de ACELYRIN durante 90 días después de la llamada, brindando amplias oportunidades para que los interesados revisen la información presentada.
ACELYRIN, INC. (Nasdaq: SLRN)는 면역학 전문의 후기 단계 임상 생명 제약 회사로, 2024년 2분기 재무 실적 및 기업 업데이트를 발표했습니다. 회사는 2024년 8월 13일 화요일 오후 5:00 ET에 이 문제를 논의하기 위해 컨퍼런스 콜을 주최할 것입니다. 투자자와 관심 있는 당사자는 회사 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 라이브 웹캐스트에 접속할 수 있습니다. 라이브 이벤트에 참석할 수 없는 분들을 위해 콜 이후 90일 동안 ACELYRIN 웹사이트에서 웹캐스트 재생이 가능하며, 이해관계자들이 발표된 정보를 검토할 수 있는 충분한 기회를 제공합니다.
ACELYRIN, INC. (Nasdaq: SLRN), une entreprise biopharmaceutique clinique en phase avancée spécialisée dans l'immunologie, a annoncé ses résultats financiers du deuxième trimestre 2024 et une mise à jour d'entreprise. La société tiendra une conférence téléphonique le mardi 13 août 2024 à 17h00 ET pour discuter de ces questions. Les investisseurs et les parties intéressées peuvent accéder à un webinaire en direct de la conférence téléphonique via le site web de l'entreprise dans la section Événements et Présentations. Pour ceux qui ne peuvent pas assister à l'événement en direct, une rediffusion du webinaire sera disponible sur le site d'ACELYRIN pendant 90 jours après l'appel, offrant ainsi de nombreuses opportunités aux parties prenantes de revoir les informations présentées.
ACELYRIN, INC. (Nasdaq: SLRN), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf Immunologie spezialisiert hat, hat die bevorstehenden Finanzergebnisse des zweiten Quartals 2024 und ein Unternehmensupdate angekündigt. Das Unternehmen wird am Dienstag, den 13. August 2024, um 17:00 Uhr ET eine Konferenzschaltung abhalten, um diese Angelegenheiten zu besprechen. Investoren und Interessierte können über die Website des Unternehmens im Bereich Veranstaltungen & Präsentationen auf ein Live-Webcast der Konferenzschaltung zugreifen. Für diejenigen, die nicht an der Live-Veranstaltung teilnehmen können, wird eine Wiedergabe des Webcasts 90 Tage lang auf der Website von ACELYRIN verfügbar sein, was den Interessierten ausreichend Gelegenheit bietet, die präsentierten Informationen zu überprüfen.
- ACELYRIN is a late-stage clinical biopharma company, indicating advanced progress in drug development
- The company is publicly traded on Nasdaq, providing liquidity for investors
- ACELYRIN is offering transparency by hosting a public conference call for financial results and corporate updates
- None.
LOS ANGELES, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Tuesday, August 13, 2024 at 5:00 p.m. ET to discuss its second quarter 2024 financial results and provide a corporate update.
A live webcast of the conference call will be available on the Company’s website under Events & Presentations. A replay of the webcast will be available on the Company’s website for 90 days.
About ACELYRIN, INC.
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. ACELYRIN has two programs in late-stage clinical development. Lonigutamab is a subcutaneously delivered monoclonal antibody targeting IGF-1R advancing into Phase 2b/3 development for the treatment of thyroid eye disease. Izokibep is a next generation inhibitor of IL-17A in Phase 2b/3 development for the treatment of psoriatic arthritis, hidradenitis suppurativa and uveitis.
For more information about ACELYRIN, visit us at www.acelyrin.com or follow us on LinkedIn and X.
Forward Looking Statements
Some statements in this press release are, or may be considered, forward-looking statements, including statements regarding ACELYRIN’s progress, business plans and clinical trials, as well as the potential future benefits of our product candidates. While ACELYRIN, INC. considers any projections to be based on reasonable assumptions, these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated in such forward-looking statements.
ACELYRIN Contacts:
Tyler Marciniak
Vice President of Investor Relations
and Corporate Affairs
investors@acelyrin.com
media@acelyrin.com
FAQ
When will ACELYRIN, INC. (SLRN) report its Q2 2024 financial results?
How can investors access ACELYRIN's (SLRN) Q2 2024 earnings call?
For how long will the replay of ACELYRIN's (SLRN) Q2 2024 earnings call be available?
What is ACELYRIN's (SLRN) primary focus as a biopharma company?
